Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.61 -0.7%	$3.13	$0.92 ▼ $4.08	$950.74M	0.88	3.16 million shs	1.57 million shs
ALT Altimmune	$4.76 -2.9%	$5.70	$2.90 ▼ $11.16	$386.07M	0.47	3.34 million shs	6.33 million shs
ETNB 89BIO	$10.14 +0.4%	$9.26	$4.16 ▼ $11.84	$1.48B	1.28	1.52 million shs	1.94 million shs
FBIO Fortress Biotech	$1.91 +4.3%	$1.82	$1.33 ▼ $2.89	$55.59M	1.75	412,266 shs	180,983 shs
FLXN Flexion Therapeutics	$25.08	$9.20	$4.30 ▼ $13.66	$1.26B	1.53	1.18 million shs	2 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	0.00%	-1.23%	-2.30%	+103.67%	+280.88%
ALT Altimmune	0.00%	+36.00%	-12.82%	+12.26%	-27.88%
ETNB 89BIO	0.00%	+2.84%	+1.81%	+75.74%	+35.56%
FBIO Fortress Biotech	0.00%	+4.89%	+1.54%	+25.59%	+8.47%
FLXN Flexion Therapeutics	0.00%	+175.00%	+175.00%	+175.00%	+175.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.2524 of 5 stars	3.6	4.0	0.0	4.0	2.0	0.8	0.6
ALT Altimmune	2.2023 of 5 stars	3.5	1.0	0.0	0.0	2.4	1.7	0.6
ETNB 89BIO	1.5624 of 5 stars	3.5	1.0	0.0	0.0	1.1	0.8	0.6
FBIO Fortress Biotech	2.1335 of 5 stars	3.5	1.0	0.0	0.0	0.6	3.3	0.6
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	87.24% Upside
ALT Altimmune	3.00	Buy	$19.00	299.16% Upside
ETNB 89BIO	3.00	Buy	$26.43	160.64% Upside
FBIO Fortress Biotech	3.00	Buy	$21.00	1,000.05% Upside
FLXN Flexion Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AKBA, FBIO, ETNB, FLXN, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/27/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/11/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/10/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/30/2025	ETNB 89BIO	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.91	N/A	N/A	($0.23) per share	-15.67
ALT Altimmune	$20K	19,304.18	N/A	N/A	$1.74 per share	2.74
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
FBIO Fortress Biotech	$57.67M	0.98	N/A	N/A	($0.06) per share	-31.82
FLXN Flexion Therapeutics	$85.55M	14.75	N/A	N/A	($0.34) per share	-73.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
ETNB 89BIO	-$367.08M	-$3.38	N/A	N/A	N/A	N/A	-81.44%	-70.17%	8/4/2025 (Estimated)
FBIO Fortress Biotech	-$46M	-$2.23	N/A	N/A	N/A	-71.24%	-4,712.53%	-27.67%	8/12/2025 (Estimated)
FLXN Flexion Therapeutics	-$113.71M	-$2.01	N/A	N/A	N/A	-100.32%	N/A	-44.26%	N/A

Latest AKBA, FBIO, ETNB, FLXN, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/1/2025	Q1 2025	ETNB 89BIO	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
ALT Altimmune	N/A	15.85	15.85
ETNB 89BIO	0.06	18.03	18.03
FBIO Fortress Biotech	1.74	1.72	1.55
FLXN Flexion Therapeutics	N/A	4.38	4.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
ALT Altimmune	78.05%
ETNB 89BIO	N/A
FBIO Fortress Biotech	96.51%
FLXN Flexion Therapeutics	90.01%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
ALT Altimmune	4.10%
ETNB 89BIO	2.80%
FBIO Fortress Biotech	27.90%
FLXN Flexion Therapeutics	9.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
ETNB 89BIO	40	145.98 million	141.90 million	Optionable
FBIO Fortress Biotech	170	29.57 million	21.32 million	Optionable
FLXN Flexion Therapeutics	257	50.32 million	45.73 million	No Data

AKBA, FBIO, ETNB, FLXN, and ALT Headlines

Recent News About These Companies

War Robots is coming to alternative storefronts following MY.GAMES and Flexion's collaboration

October 3, 2024 | pocketgamer.comP

Flexion wins contract to support CFPB in evaluating financial education content

April 25, 2024 | finance.yahoo.com

Flexion awarded contract to revolutionize Head Start’s Data Management System

April 19, 2024 | finance.yahoo.com

Flexion Joins AWS Public Sector Partner Program, Enhancing Commitment to Public Sector Software Projects

April 11, 2024 | tmcnet.com

VIRI Virios Therapeutics, Inc.

April 6, 2024 | seekingalpha.com

Spyre Therapeutics Inc SYRE

February 14, 2024 | morningstar.comM

PFIZER INC's Net Worth

February 10, 2024 | benzinga.com

Flexion/Extension Fluoroscopy of C-Spine is Inadequate

January 12, 2024 | medscape.comM

SpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, Predictions

November 24, 2023 | benzinga.com

Flexion Mobile: Cuts 2023 sales forecast on softer Q3 - ABG

November 6, 2023 | nyheter24.seN

Oppo Unveils Find N3: Foldable Phone with Flexion Hinge and Snapdragon 8 Gen 2

October 19, 2023 | newsd.inN

Flexion wins MCADS contract to modernize CMS Claims Handling System

July 11, 2023 | benzinga.com

Flexion achieves Select Tier Status within the AWS Partner Network

July 10, 2023 | finance.yahoo.com

7 Exercises to Stretch Plantar Flexion Movement

June 10, 2023 | yahoo.com

Pain Therapeutics conference is taking place in London next week

June 8, 2023 | pharmaphorum.comP

Flexion Mobile: Notice of Annual General Meeting

May 31, 2023 | privataaffarer.seP

2023-2029 Flexion Tires Market Growth Prospects and Countries Analysis | with 91 Pages

May 16, 2023 | marketwatch.com

OPPO Find N2 Flip's Flexion Hinge Marks A Breakthrough In Flip Phone Experience

May 4, 2023 | finance.yahoo.com

Prone Leg Flexion Trainers Market Global Outlook and Projection till 2029

April 28, 2023 | marketwatch.com

Abdominal Flexion Training Device Market Research & Size Analysis 2023-2028

April 12, 2023 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, FBIO, ETNB, FLXN, and ALT Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.60 -0.03 (-0.69%)

Closing price 07/3/2025 02:45 PM Eastern

Extended Trading

$3.62 +0.01 (+0.28%)

As of 07/3/2025 04:58 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Altimmune NASDAQ:ALT

$4.76 -0.14 (-2.86%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$4.76 +0.00 (+0.08%)

As of 07/3/2025 04:59 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

89BIO NASDAQ:ETNB

$10.14 +0.04 (+0.40%)

Closing price 07/3/2025 02:41 PM Eastern

Extended Trading

$10.14 -0.01 (-0.05%)

As of 07/3/2025 04:20 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Fortress Biotech NASDAQ:FBIO

$1.91 +0.08 (+4.32%)

As of 07/3/2025 03:36 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Flexion Therapeutics NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time